When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPSEY - Cabometyx approved in Europe for first-line kidney cancer; Exelixis up 5% premarket
Ipsen SA ADR
Exelixis (NASDAQ:EXEL) is up 5% premarket, albeit on only 100 shares, in response to its announcement that the European Commission has approved commercialization partner Ipsen's (OTCPK:IPSEY)(OTCPK:IPSEF) marketing application for CABOMETYX (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (RCC).
More news on: Exelixis, Inc., Ipsen S.A. ADR, Ipsen S.A., Healthcare stocks news, Stocks on the move,